ORIGINAL ARTICLE Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab List of authors. Anil Gupta, M.D., Yaneicy Gonzalez-Rojas, M.D., Erick Juarez, M.D., Manuel Crespo Casal, M.D., et al., for the COMET-ICE Investigators * October 27, 2021 DOI: 10.1056/NEJMoa2107934 Article Figures/Media Metrics 27 References Abstract BACKGROUND Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease. METHODS In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a...